Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 388 matching trials from the live ClinicalTrials.gov search.
Conditions
Extragonadal Germ Cell Tumor, Ovarian Cancer
Interventions
dactinomycin, filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, vincristine sulfate, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8
Interventions
Discussion, Informational Intervention, Media Intervention, Questionnaire Administration, Telephone-Based Intervention
Procedure · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
pegfilgrastim, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Seattle, Washington
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, etoposide phosphate, paclitaxel, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Conditions
Ovarian Cancer
Interventions
radionuclide imaging, indium In 111 folic acid
Procedure · Radiation
Lead sponsor
Endocyte
Industry
Eligibility
18 Years to 120 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Houston, Texas
Conditions
Fallopian Tube Cancer, Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Uterine Sarcoma, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Uterine Sarcoma, Stage IV Vulvar Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
Interventions
stereotactic radiosurgery, quality-of-life assessment
Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Primary Hepatocellular Carcinoma, Adult Subependymoma, Advanced Adult Primary Liver Cancer, Advanced Malignant Mesothelioma, Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Malignant Mesothelioma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage II Esophageal Cancer, Stage II Pancreatic Cancer, Stage III Esophageal Cancer, Stage III Pancreatic Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Results available

Ovarian Cancer Patient-Centered Decision Aid

NCT02259699
Conditions
Stage III Ovarian Cancer
Interventions
Decision Aid
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Irvine, California
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Choriocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Dysgerminoma, Ovarian Embryonal Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Mucinous Cystadenocarcinoma, Ovarian Polyembryoma, Ovarian Sarcoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Stage I Ovarian Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Cognitive Assessment, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
182
States / cities
Tucson, Arizona • Little Rock, Arkansas • Burbank, California + 129 more
Conditions
Ovarian Cancer
Interventions
Vigil™
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
7
States / cities
West Palm Beach, Florida • Lebanon, New Hampshire • Hackensack, New Jersey + 3 more
Conditions
Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions
HER-2/neu intracellular domain protein, therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
Interventions
Gemcitabine, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 51 more
Conditions
Stage II Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer, Stage II Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage II Cervical Cancer, Stage III Cervical Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Stage II Kidney Cancer, Stage III Kidney Cancer, Stage IV Kidney Cancer
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 5 more
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Interventions
Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Uterine Cancer
Interventions
Olaparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Edmonds, Washington • Issaquah, Washington • Seattle, Washington
Conditions
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
TRPV6 Calcium Channel Inhibitor SOR-C13
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BMS-247550
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington